CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
carboplatin +2 moredrug
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Histologically confirmed progressive and/or symptomatic low-grade glioma (WHO grade I or II astrocytoma, oligodendrogliomas, mixed oligodendrogliomas, or gangliogliomas)
  • ✓Age 10 years and under
  • ✓Measurable disease
  • ✓Optic pathway tumors allowed if showing evidence of progressive disease by MRI and/or visual or endocrine deterioration
Key exclusion· 4
  • ✕Diffuse brainstem gliomas
  • ✕Type 1 neurofibromatosis
  • ✕Concurrent immunomodulating agents
  • ✕Other concurrent anticancer chemotherapy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00077207
NCT00077207N/ACompleted
CompareCT.gov

A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas

Children's Oncology Group·interventional·Posted Feb 11, 2004·Updated May 16, 2018

In Brief

A clinical study evaluating carboplatin, temozolomide, and 1 other intervention for Brain Tumor and Central Nervous System Tumor. Completed, enrolled 66 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin, vincristine, and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: This pilot study is studying giving carboplatin and vincristine together with temozolomide in treating children with progressive and/or symptomatic low-grade glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumor, Central Nervous System Tumor
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 11, 2004
Enrollment StartJul 1, 2004
Primary CompletionMar 1, 2010
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 22.4 years ago

Interventions

carboplatindrug

Given IV

temozolomidedrug

Given orally

vincristine sulfatedrug

Given IV